Capecitabine App in Metastatic Breast Cancer, version 1
Research type
Research Study
Full title
Evaluation Of CanADVICE+®M-Health System To Support Breast Cancer Patients Receiving Capecitabine
IRAS ID
174504
Contact name
Jillian Noble
Contact email
Sponsor organisation
Clinical R&D office
Duration of Study in the UK
2 years, 0 months, 0 days
Research summary
The purpose of the study is to pilot an android mobile phone app, developed by Kingston University, to support cancer patients receiving oral anticancer therapy. The app known as CanADVICE+® is a secure system that reminds patients when to take their Capecitabine medication, gives advice on how to manage their side effects of Capecitabine, and has the capacity for patients to send alerts to healthcare professionals in the case of serious side effects occurring. The app is securely linked to the healthcare team at The Royal Marsden, who are able to access the medical records following an alert and contact the patient by phone to provide advice. It is hoped that through this direct link, early detection and management of any side effects will avoid more serious side effects and also may avoid hospital admissions.
REC name
London - Surrey Research Ethics Committee
REC reference
15/LO/1849
Date of REC Opinion
19 Nov 2015
REC opinion
Further Information Favourable Opinion